Expedition Therapeutics secured a licensing deal worth up to $645 million to develop and commercialize Fosun Pharma’s experimental DPP-1 inhibitor outside China, marking its first public drug acquisition. Backed by prominent investors, Expedition’s strategy focuses on bringing China-originated drugs to Western markets, tapping into a growing biotech trend amid robust innovation in China’s pharmaceutical sector. The candidate targets inflammatory pathways implicated in several lung diseases, aligning with previous DPP-1 drug successes in bronchiectasis.